CRAVE study: GLP-1, food cravings, and diet

A prospective study published in Obesity Pillars in September 2026 tracked 28 adults on GLP-1 receptor agonist therapy for 24 weeks and measured four things in parallel: food cravings, diet quality, body composition, and total dietary intake^[1]. The CRAVE study is one of the first prospective datasets to look at all four variables together in a single cohort, rather than inferring dietary effects from weight-loss trial secondary endpoints.

The short version: participants ate less, lost weight, and saw roughly a quarter of that weight come from estimated skeletal muscle mass. Food cravings did not change on average, though people who started with high craving scores saw a larger reduction. Diet quality did not improve, and several key micronutrients dropped across the 24 weeks. The authors are clear that these findings are exploratory given the small sample, but they raise questions that larger trials have not yet answered.

Weight loss and body composition

Participants lost weight and showed significant reductions in adiposity over the 24-week period^[1]. The composition of that weight loss matters. The study found that approximately one quarter of the reduction came from estimated skeletal muscle mass. This proportion sits in the same neighbourhood as broader clinical observations about weight loss from any cause, but it draws attention in the GLP-1 context because people on these medications are often losing weight faster than they would through lifestyle change alone.

Higher absolute protein intake was associated with greater preservation of skeletal muscle^[1]. This is consistent with the general nutrition literature, where adequate protein intake is the primary modifiable factor in limiting lean mass loss during weight reduction. Whether that association holds causally, and at what protein targets, remains an open question that a 28-person exploratory study cannot settle.

Food cravings: high baseline, greater change

Overall, food cravings were unchanged across the study group^[1]. That finding may seem to conflict with the widely reported subjective experience of GLP-1 class medications quieting food preoccupation, sometimes called food noise in the clinical literature. The CRAVE data offer one explanation: the effect appears concentrated in people who started with elevated craving scores. Among that subgroup, the correlation between baseline craving level and craving reduction was -0.69, meaning those who entered the study with the highest cravings saw the largest reductions.

In other words, the medication may not suppress cravings uniformly. For people whose cravings were already low at baseline, there may be little room to move. The average across both groups combined ends up near zero. This is a plausible pattern but requires replication in larger, controlled studies before any confident conclusion can be drawn.

Diet quality and micronutrients

Despite eating less and losing weight, participants did not show a significant improvement in diet quality^[1]. That is a meaningful observation. It suggests that the appetite-reducing effect of GLP-1 receptor agonists does not automatically shift people toward more nutritious food choices. They eat less of what they were eating before, not necessarily better food.

Alongside the diet quality finding, the study recorded significant declines in intake across multiple micronutrients over the 24 weeks^[1]. The researchers do not name which micronutrients specifically in the abstract, but the direction is consistent with a general reduction in food volume without a corresponding shift toward nutrient-dense choices. If micronutrient gaps develop quietly during therapy, they could compound over longer treatment periods, which for many patients will extend well beyond six months.

Context: what larger trials show

The CRAVE findings sit inside a larger picture. SURMOUNT-4, which followed 670 participants on tirzepatide through 88 weeks and then randomised them to continued treatment or placebo, confirmed that tirzepatide produces substantial and sustained weight loss when therapy continues: 89.5% of the tirzepatide group maintained at least 80% of their prior weight loss at week 88^[2]. What SURMOUNT-4 was not designed to measure is what happens to diet quality and micronutrient status over that same period.

The STEP 1 trial extension for semaglutide adds another layer: when participants stopped treatment, they regained approximately two-thirds of the weight they had lost within 12 months^[3]. The observation that GLP-1 class therapy requires ongoing use to sustain its effects makes the CRAVE micronutrient and diet quality questions more pressing. A patient on these medications for several years, eating less but not better, may be accumulating nutritional gaps that clinical teams are not routinely measuring.

What we do not yet know

The CRAVE study enrolled 28 participants and the authors describe the findings as exploratory and hypothesis-generating. There was no control group, the dietary measures relied on self-report, and participant attrition limits the confidence that can be placed on any single finding. The study cannot tell us which micronutrients are most at risk, whether the muscle loss proportion changes at different weight-loss speeds, or whether dietary counselling during GLP-1 therapy would shift the diet quality result.

What it can do is point toward the studies needed next. The CRAVE team have published a dataset that, if replicated with a larger sample and a control arm, would have real clinical relevance for the growing number of patients on tirzepatide and semaglutide. Whether they eat better, preserve more muscle, and maintain their micronutrient status over years of treatment are questions worth a proper randomised answer.

Medical disclaimer

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides and medications discussed may be classified as prescription medicines depending on your jurisdiction. Always consult a qualified healthcare professional before using any medication or changing your diet. PeptideMethods.com does not sell, distribute, or facilitate the sale of any product.